SOMATOSTATIN ANALOGS
Liver burden disease
PROMID
CLARINET
18.8% of patients 33% of patients
Rinke A, et al. Neuroendocrinology 2017;104:26–32
Caplin M, et al. N Engl J Med 2014; 371:224-233
Liver tumor load > 25%
OS in hepatic tumor load ≤ 10% vs > 10%